<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04093440</url>
  </required_header>
  <id_info>
    <org_study_id>HCV-19-001</org_study_id>
    <nct_id>NCT04093440</nct_id>
  </id_info>
  <brief_title>Cardiometabolic Syndrome Response to Therapeutic Lifestyle Changes</brief_title>
  <acronym>COSMETIC</acronym>
  <official_title>CardiOmetabolic SyndroME Response to Therapeutic lIfestyle Changes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Holy Cross Hospital, Florida</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Holy Cross Hospital, Florida</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Intensive lifestyle intervention has shown to be effective in high risk patient populations
      and has gathered support from leaders—as outlined in the 2015 consensus paper by the
      Cardiometabolic Health Alliance. Thus there has been a call to establish new care models that
      assist Metabolic Syndrome patients in reducing there risk. The investigators aim to evaluate
      the impact of a lifestyle intervention program on metabolic syndrome patients.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 2019</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">October 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reversal of metabolic syndrome</measure>
    <time_frame>At the end of 12 months</time_frame>
    <description>Change in number of metabolic syndrome risk factors</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>within three to five years of intervention</time_frame>
    <description>KM curve of patients with change in metabolic risk factors vs those with no change</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hemoglobin A1c</measure>
    <time_frame>At the end of 12 months</time_frame>
    <description>change in hemoglobin A1c (percentage)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>waist circumference</measure>
    <time_frame>At the end of 12 months</time_frame>
    <description>change in waist circumference (inches)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>blood pressure</measure>
    <time_frame>At the end of 12 months</time_frame>
    <description>change in average blood pressure (mmHg)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>total cholesterol</measure>
    <time_frame>At the end of 12 months</time_frame>
    <description>change in total cholesterol (mg/dL)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Metabolic Syndrome</condition>
  <condition>ASCVD</condition>
  <condition>Lifestyle Risk Reduction</condition>
  <arm_group>
    <arm_group_label>Observation</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>lifestyle modification: nutrition counselling, diet and physical exercise monitoring, smoking cessation, and medication optimization</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>lifestyle modification</intervention_name>
    <description>nutrition counselling, diet and physical exercise monitoring, smoking cessation, and medication optimization</description>
    <arm_group_label>Observation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Metabolic syndrome patients meeting 3 of 5 criteria:

               1. waist circumference (37 in) in white and AA men, (35 in) in Asian men, and (31.5
                  in) in women;

               2. triglycerides ≥150 mg/dl;

               3. high-density lipoprotein cholesterol (HDL-C) &lt;40 mg/dl in men and &lt;50 mg/dl in
                  women;

               4. blood pressure ≥130/85 mm Hg

               5. fasting glucose ≥100 mg/d or HgbA1c ≥ 5.71 (includes diabetics)

          -  Patients requiring secondary ASCD prevention

        Exclusion Criteria:

          -  Patients with less than 5 year survival

          -  Patients with cancer undergoing therapy or on palliative treatment

          -  Patients with end stage heart failure
      </textblock>
    </criteria>
    <gender>All</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Charles Russo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jim Moran Heart and Vascular Research Center at Holy Cross Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Paul Papagni, JD</last_name>
    <role>Study Director</role>
    <affiliation>Jim Moran Heart and Vascular Research Center at Holy Cross Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Charles Russo, MD</last_name>
    <phone>9547718000</phone>
    <email>chuckiedrusso@aol.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Abdullah Sarkar, MD</last_name>
    <phone>4698183688</phone>
    <email>axs2500@miami.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Internal Medicine Residency Clinic at Holy Cross Hospital</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33334</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Charles Russo, MD</last_name>
      <phone>954-491-2160</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>September 5, 2019</study_first_submitted>
  <study_first_submitted_qc>September 16, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 18, 2019</study_first_posted>
  <last_update_submitted>September 16, 2019</last_update_submitted>
  <last_update_submitted_qc>September 16, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 18, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cardiometabolic clinic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metabolic Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

